Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 4/20 | 0.40 |
| ▸ | MMP9 | P14780 | 4/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 2/20 | 0.39 |
| ▸ | MMP13 | P45452 | 2/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.38 |
| ▸ | ACP1 | P24666 | 3/20 | 0.38 |
| ▸ | CDC25B | P30305 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 8/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3239425 | 1.00 | MMP2 (0.40) | MMP2MMP9MMP3MMP8MMP13 | |
| SCHEMBL3239913 | 1.00 | MMP2 (0.40) | MMP2MMP9MMP3MMP8MMP13 | |
| SCHEMBL3242954 | 0.93 | ALDH1A1 (0.35) | MMP2MMP9MMP3PTPN1ACP1 | |
| SCHEMBL4656839 | 0.90 | MMP9 (0.34) | MMP2MMP9MMP3MMP8MMP13 | |
| SCHEMBL3750812 | 0.77 | — | — | |
| SCHEMBL17307320 | 0.76 | SIRT2 (0.38) | MMP2MMP9MMP3PTPN1ACP1 | |
| SCHEMBL3237199 | 0.74 | AKT1 (0.32) | MMP9 | |
| SCHEMBL3239526 | 0.67 | ACHE (0.43) | PTPN1ACP1CDC25BALOX5 | |
| SCHEMBL21415447 | 0.64 | PTPN1 (0.45) | MMP2MMP9MMP3MMP8MMP13 | |
| SCHEMBL21961902 | 0.63 | SIRT2 (0.45) | PTPN1ACP1CDC25BSIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100291275-A1 | Flavorant and Fragrance Furan-2(5H)-One Compounds | GIVAUDAN SA (CH) | 2010-11-18 | — | — | US | disclosed |
| EP-1996569-B1 | FLAVORANT AND FRAGRANCE COMPOUNDS | GIVAUDAN SA (CH) | 2010-07-28 | — | — | EP | disclosed |
| EP-1996569-A1 | FLAVORANT AND FRAGRANCE COMPOUNDS | Givaudan SA (CH) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007107023-A1 | FLAVORANT AND FRAGRANCE COMPOUNDS | GIVAUDAN SA (CH) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100291275-A1 | Flavorant and Fragrance Furan-2(5H)-One Compounds | TAS2R5, TAS2R1, TAS1R1 | MMP2 4652/4885MMP9 4578/4885MMP3 4784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.